{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:31:45Z","timestamp":1792009905213,"version":"4.4.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatol Commun"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:p>\n                    Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. n\u20103 polyunsaturated fatty acids (n\u20103\u2010PUFAs) have been reported to ameliorate the progression of NAFLD in experimental studies; however, clinical trials have yielded contradictory results. The aim of our study was to assess the effects of n\u20103\u2010PUFA administration on lipid metabolism and the progression of NAFLD in patients with metabolic syndrome. Sixty patients with metabolic syndrome and NAFLD were randomized in a double\u2010blind placebo\u2010controlled trial (3.6 g\/day n\u20103\u2010PUFA vs. placebo). During the 1\u2010year follow\u2010up, the patients underwent periodic clinical and laboratory examinations, liver stiffness measurements, magnetic resonance spectroscopy of the liver, and plasma lipidomic analyses. After 12 months of n\u20103\u2010PUFA administration, a significant decrease in serum GGT activity was recorded compared with the placebo group (2.03 \u00b1 2.8 vs. 1.43 \u00b1 1.6;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.05). Although no significant changes in anthropometric parameters were recorded, a significant correlation between the reduction of liver fat after 12 months of treatment\u2014and weight reduction\u2014was observed; furthermore, this effect was clearly potentiated by n\u20103\u2010PUFA treatment (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.005). In addition, n\u20103\u2010PUFA treatment resulted in substantial changes in the plasma lipidome, with n\u20103\u2010PUFA\u2010enriched triacylglycerols and phospholipids being the most expressed lipid signatures.\n                    <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic>\n                    Twelve months of n\u20103\u2010PUFA treatment of patients with NAFLD patients was associated with a significant decrease in GGT activity, the liver fat reduction in those who reduced their weight, and beneficial changes in the plasma lipid profile.\n                  <\/jats:p>","DOI":"10.1002\/hep4.1906","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T06:10:20Z","timestamp":1644559820000},"page":"1336-1349","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":82,"title":["Effect of Omega\u20103 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients With Metabolic Syndrome and NAFLD"],"prefix":"10.1097","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8664-7918","authenticated-orcid":false,"given":"V\u00e1clav","family":"\u0160m\u00edd","sequence":"first","affiliation":[{"name":"Fourth Department of Internal Medicine,First Faculty of Medicine and General University Hospital in Prague,Charles University,Prague,Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Dvo\u0159\u00e1k","sequence":"additional","affiliation":[{"name":"Fourth Department of Internal Medicine,First Faculty of Medicine and General University Hospital in Prague,Charles University,Prague,Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"\u0160ediv\u00fd","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology,Institute for Clinical and Experimental Medicine,Prague,Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edt","family":"Kosek","sequence":"additional","affiliation":[{"name":"Department of Food Analysis and Nutrition,University of Chemistry and Technology,Prague,Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Len\u00ed\u010dek","sequence":"additional","affiliation":[{"name":"Institute of Medical Biochemistry and Laboratory Diagnostics,First Faculty of Medicine and General University Hospital in Prague,Charles University,Prague,Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Dezortov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology,Institute for Clinical and Experimental Medicine,Prague,Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Haj\u0161lov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Food Analysis and Nutrition,University of Chemistry and Technology,Prague,Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"H\u00e1jek","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology,Institute for Clinical and Experimental Medicine,Prague,Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5318-0151","authenticated-orcid":false,"given":"Libor","family":"V\u00edtek","sequence":"additional","affiliation":[{"name":"Fourth Department of Internal Medicine,First Faculty of Medicine and General University Hospital in Prague,Charles University,Prague,Czech Republic"},{"name":"Institute of Medical Biochemistry and Laboratory Diagnostics,First Faculty of Medicine and General University Hospital in Prague,Charles University,Prague,Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"Bechy\u0148sk\u00e1","sequence":"additional","affiliation":[{"name":"Department of Food Analysis and Nutrition,University of Chemistry and Technology,Prague,Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9924-4301","authenticated-orcid":false,"given":"Radan","family":"Br\u016fha","sequence":"additional","affiliation":[{"name":"Fourth Department of Internal Medicine,First Faculty of Medicine and General University Hospital in Prague,Charles University,Prague,Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"key":"hep41906-bib-0001-20251121","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/jhep.2003.50161","article-title":"Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome","volume":"37","year":"2003","journal-title":"Hepatology"},{"key":"hep41906-bib-0002-20251121","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non\u2010alcoholic fatty liver disease and non\u2010alcoholic steatohepatitis in adults","volume":"34","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"hep41906-bib-0003-20251121","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"hep41906-bib-0004-20251121","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","year":"2019","journal-title":"Hepatology"},{"key":"hep41906-bib-0005-20251121","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(16)30054-X","article-title":"Trends in adult body\u2010mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population\u2010based measurement studies with 19.2 million participants","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"hep41906-bib-0006-20251121","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/hep.23314","article-title":"Decreased survival of subjects with elevated liver function tests during a 28\u2010year follow\u2010up","volume":"51","year":"2010","journal-title":"Hepatology"},{"key":"hep41906-bib-0007-20251121","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"hep41906-bib-0008-20251121","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/medicines6010041","article-title":"The epidemiology, risk profiling and diagnostic challenges of nonalcoholic fatty liver disease","volume":"6","year":"2019","journal-title":"Medicines"},{"key":"hep41906-bib-0009-20251121","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/ng.3855","article-title":"Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci","volume":"49","year":"2017","journal-title":"Nat Genet"},{"key":"hep41906-bib-0010-20251121","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/hep.24283","article-title":"Meta\u2010analysis of the influence of I148M variant of patatin\u2010like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease","volume":"53","year":"2011","journal-title":"Hepatology"},{"key":"hep41906-bib-0011-20251121","doi-asserted-by":"crossref","first-page":"355","DOI":"10.12998\/wjcc.v6.i10.355","article-title":"PNPLA3 rs139051 is associated with phospholipid metabolite profile and hepatic inflammation in nonalcoholic fatty liver disease","volume":"6","year":"2018","journal-title":"World J Clin Cases"},{"key":"hep41906-bib-0012-20251121","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jhep.2015.07.036","article-title":"Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME trial","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"hep41906-bib-0013-20251121","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"key":"hep41906-bib-0014-20251121","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL\u2010EASD\u2010EASO clinical practice guidelines for the management of non\u2010alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"hep41906-bib-0015-20251121","first-page":"103","article-title":"Omega\u20103 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand?","volume":"22","year":"2019","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"hep41906-bib-0016-20251121","article-title":"Oxidative stress and non\u2010alcoholic fatty liver disease: effects of omega\u20103 fatty acid supplementation","volume":"11","year":"2019","journal-title":"Nutrients"},{"key":"hep41906-bib-0017-20251121","article-title":"Omega\u20103 polyunsaturated fatty acid supplementation and non\u2010alcoholic fatty liver disease: a meta\u2010analysis of randomized controlled trials","volume":"97","year":"2018","journal-title":"Medicine"},{"key":"hep41906-bib-0018-20251121","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.pharmthera.2017.07.007","article-title":"Omega\u20103 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease","volume":"181","year":"2018","journal-title":"Pharmacol Ther"},{"key":"hep41906-bib-0019-20251121","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/hep4.1188","article-title":"Metabolomic\u2010based noninvasive serum test to diagnose nonalcoholic steatohepatitis: results from discovery and validation cohorts","volume":"2","year":"2018","journal-title":"Hepatol Commun"},{"key":"hep41906-bib-0020-20251121","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.3748\/wjg.v25.i24.3009","article-title":"Biomarkers and subtypes of deranged lipid metabolism in non\u2010alcoholic fatty liver disease","volume":"25","year":"2019","journal-title":"World J Gastroenterol"},{"key":"hep41906-bib-0021-20251121","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","year":"2009","journal-title":"Circulation"},{"key":"hep41906-bib-0022-20251121","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"hep41906-bib-0023-20251121","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB\u20104: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest","volume":"46","year":"2007","journal-title":"Hepatology"},{"key":"hep41906-bib-0024-20251121","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","year":"2007","journal-title":"Hepatology"},{"key":"hep41906-bib-0025-20251121","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10334-011-0264-9","article-title":"MR spectroscopy as a tool for in vivo determination of steatosis in liver transplant recipients","volume":"24","year":"2011","journal-title":"MAGMA"},{"key":"hep41906-bib-0026-20251121","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jhep.2007.09.009","article-title":"Nutritional assessment and hepatic fatty acid composition in non\u2010alcoholic fatty liver disease (NAFLD): a cross\u2010sectional study","volume":"48","year":"2008","journal-title":"J Hepatol"},{"key":"hep41906-bib-0027-20251121","doi-asserted-by":"crossref","first-page":"481","DOI":"10.21037\/atm.2016.12.27","article-title":"Gamma\u2010glutamyl transferase and cardiovascular disease","volume":"4","year":"2016","journal-title":"Ann Transl Med"},{"key":"hep41906-bib-0028-20251121","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.annepidem.2014.09.001","article-title":"Gamma\u2010glutamyl transferase and risk of type II diabetes: an updated systematic review and dose\u2010response meta\u2010analysis","volume":"24","year":"2014","journal-title":"Ann Epidemiol"},{"key":"hep41906-bib-0029-20251121","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1161\/ATVBAHA.107.152298","article-title":"Gamma\u2010glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta\u2010Analysis","volume":"27","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"hep41906-bib-0030-20251121","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.clnu.2017.01.006","article-title":"Non\u2010alcoholic fatty liver disease and its treatment with n\u20103 polyunsaturated fatty acids","volume":"37","year":"2018","journal-title":"Clin Nutr"},{"key":"hep41906-bib-0031-20251121","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jpeds.2015.01.056","article-title":"Omega\u20103 fatty acids therapy in children with nonalcoholic fatty liver disease: a randomized controlled trial","volume":"166","year":"2015","journal-title":"J Pediatr"},{"key":"hep41906-bib-0032-20251121","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.gastro.2014.04.046","article-title":"EPE\u2010A Study Group. No significant effects of ethyl\u2010eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial","volume":"147","year":"2014","journal-title":"Gastroenterology"},{"key":"hep41906-bib-0033-20251121","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-nutr-071812-161139","article-title":"Fatty acid\u2010regulated transcription factors in the liver","volume":"33","year":"2013","journal-title":"Annu Rev Nutr"},{"key":"hep41906-bib-0034-20251121","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1194\/jlr.M061275","article-title":"Docosahexaenoic acid attenuates Western diet\u2010induced hepatic fibrosis in Ldlr\u2010\/\u2010 mice by targeting the TGFbeta\u2010Smad3 pathway","volume":"56","year":"2015","journal-title":"J Lipid Res"},{"key":"hep41906-bib-0035-20251121","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3945\/ajcn.116.131896","article-title":"A randomized, crossover, head\u2010to\u2010head comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation markers in men and women: the Comparing EPA to DHA (ComparED) Study","volume":"104","year":"2016","journal-title":"Am J Clin Nutr"},{"key":"hep41906-bib-0036-20251121","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jhep.2014.08.036","article-title":"Effects of n\u20103 fish oil on metabolic and histological parameters in NASH: a double\u2010blind, randomized, placebo\u2010controlled trial","volume":"62","year":"2015","journal-title":"J Hepatol"},{"key":"hep41906-bib-0037-20251121","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.bbalip.2014.08.010","article-title":"Marine omega\u20103 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance","volume":"1851","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"hep41906-bib-0038-20251121","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3945\/jn.112.171322","article-title":"Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr(\u2010\/\u2010) mouse model of western diet\u2010induced nonalcoholic steatohepatitis","volume":"143","year":"2013","journal-title":"J Nutr"},{"key":"hep41906-bib-0039-20251121","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.plefa.2012.12.001","article-title":"Lipidomics of hepatic lipogenesis inhibition by omega 3 fatty acids","volume":"88","year":"2013","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"hep41906-bib-0040-20251121","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.plefa.2015.04.010","article-title":"Plasma fatty acid composition in French\u2010Canadian children with non\u2010alcoholic fatty liver disease: effect of n\u20103 PUFA supplementation","volume":"99","year":"2015","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"hep41906-bib-0041-20251121","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jhep.2016.01.002","article-title":"Hepatic ceramides dissociate steatosis and insulin resistance in patients with non\u2010alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"hep41906-bib-0042-20251121","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s00125-014-3310-0","article-title":"PNPLA3 variant I148M is associated with altered hepatic lipid composition in humans","volume":"57","year":"2014","journal-title":"Diabetologia"},{"key":"hep41906-bib-0043-20251121","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ajhg.2008.09.012","article-title":"Population\u2010based genome\u2010wide association studies reveal six loci influencing plasma levels of liver enzymes","volume":"83","year":"2008","journal-title":"Am J Hum Genet"},{"key":"hep41906-bib-0044-20251121","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.mam.2018.03.001","article-title":"Omega\u20103 fatty acids and non\u2010alcoholic fatty liver disease: evidence of efficacy and mechanism of action","volume":"64","year":"2018","journal-title":"Mol Aspects Med"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep4.1906","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep4.1906","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.1906","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T15:00:23Z","timestamp":1763737223000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.1906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1002\/hep4.1906","relation":{},"ISSN":["2471-254X","2471-254X"],"issn-type":[{"value":"2471-254X","type":"print"},{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,11]]},"assertion":[{"value":"2021-09-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}